CompletedPhase 3NCT00885365

A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

Studying Body integrity dysphoria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chiesi Farmaceutici S.p.A.
Principal Investigator
Henryk Mazurek, Doctor
Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj
Intervention
tobramycin / Bramitob(drug)
Enrollment
324 enrolled
Eligibility
6 years · All sexes
Timeline
20092010

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00885365 on ClinicalTrials.gov

Other trials for Body integrity dysphoria

Additional recruiting or active studies for the same condition.

See all trials for Body integrity dysphoria

← Back to all trials